<p>Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - 獲取免費報告) 週三的期權交易異常活躍。股票投資者購買了 25,745 份該公司的看漲期權。這比平均交易量 6,521 份看漲期權增加了 295%。</p>
<p>獲取 <strong>Reviva Pharmaceuticals</strong> 的提醒：</p>
<h2>分析師升級和降級</h2>
<p>RVPH 已成為多份研究報告的主題。D. Boral Capital 在週二的報告中重申了對 Reviva Pharmaceuticals 的 &#34;買入&#34; 評級，並設定了 2.00 美元的目標價。Benchmark 在 9 月 15 日的研究報告中將 Reviva Pharmaceuticals 的目標價從 14.00 美元下調至 7.00 美元，並對該股票設定了 &#34;投機性買入&#34; 評級。HC Wainwright 在 10 月 27 日的報告中將 Reviva Pharmaceuticals 的目標價從 11.00 美元下調至 4.00 美元，並對該股票設定了 &#34;買入&#34; 評級。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Reviva Pharmaceuticals 的 &#34;賣出 (e+)&#34; 評級。最後，Wall Street Zen 在 10 月 4 日的研究報告中將 Reviva Pharmaceuticals 的評級上調至 &#34;賣出&#34;。一位投資分析師對該股票給予了強烈買入評級，七位分析師給予了買入評級，一位分析師對該公司的股票給予了賣出評級。根據 MarketBeat 的數據，該股票的共識評級為 &#34;適度買入&#34;，共識目標價為 3.86 美元。</p>
<p><strong>獲取我們對 RVPH 的最新分析</strong></p>
<h2>Reviva Pharmaceuticals 股價下跌 45.5%</h2>
<p>NASDAQ RVPH 週三開盤價為 0.32 美元。該股票的 50 日移動平均線為 0.57 美元，200 日移動平均線為 0.52 美元。該公司的市值為 3697 萬美元，市盈率為 -0.70，貝塔值為 -0.02。Reviva Pharmaceuticals 的一年低點為 0.25 美元，一年高點為 2.17 美元。</p>
<p>Reviva Pharmaceuticals (NASDAQ:RVPH - 獲取免費報告) 最近於 11 月 13 日發佈了季度財報。該公司報告每股收益為（0.06）美元，超出市場共識預期的（0.11）美元 0.05 美元。作為一個整體，股票研究分析師預測 Reviva Pharmaceuticals 本財年的每股收益將為 -0.97 美元。</p>
<h2>Reviva Pharmaceuticals 的機構交易</h2>
<p>幾家對沖基金和其他機構投資者最近對 RVPH 的持倉進行了調整。Armistice Capital LLC 在第二季度購買了價值約 1,026,000 美元的 Reviva Pharmaceuticals 新頭寸。683 Capital Management LLC 在第二季度購買了價值 381,000 美元的 Reviva Pharmaceuticals 新股份。Persistent Asset Partners Ltd 在第二季度將其在 Reviva Pharmaceuticals 的持倉增加了 300.0%。Persistent Asset Partners Ltd 現在擁有 641,174 股該公司的股票，價值 244,000 美元，此前在上個季度又購買了 480,864 股。Millennium Management LLC 在第三季度將其在 Reviva Pharmaceuticals 的持倉增加了 15.0%。Millennium Management LLC 現在擁有 1,711,221 股該公司的股票，價值 631,000 美元，此前在此期間又收購了 223,178 股。最後，Lido Advisors LLC 在第三季度購買了價值 37,000 美元的 Reviva Pharmaceuticals 新股份。對沖基金和其他機構投資者持有該公司 63.18% 的股份。</p>
<h2>Reviva Pharmaceuticals 公司簡介</h2>
<p>(獲取免費報告)</p>
<p>Reviva Pharmaceuticals, Inc NASDAQ: RVPH 是一家專注於在美國和部分國際市場收購、開發和商業化處方藥產品的專業製藥公司。公司成立於 2002 年，總部位於佛羅里達州科勒爾蓋布爾斯，Reviva 主要針對那些未被充分推廣的、已過專利期的藥物，這些藥物的新劑型可以提高患者的依從性和治療效果。</p>
<p>公司的核心活動包括識別 FDA 批准的藥物候選者，開發配方以滿足特定或服務不足的患者羣體——例如兒科和孤兒適應症——並支持監管申請。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Reviva Pharmaceuticals</li>
<li>可能每月帶來高達 4,290 美元的無聊 AI 投資</li>
<li>警報：在 2026 年 1 月之前拋售這 5 只股票！</li>
<li>特朗普的 “美國房地產交易” 解釋</li>
<li>崩盤前一個月</li>
<li>在 1 月 1 日之前投資 1,000 美元於這隻股票 [不是 NVDA]</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元於 Reviva Pharmaceuticals 嗎？</h2>
<p>在你考慮 Reviva Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Reviva Pharmaceuticals 並不在名單上。</p>
<p>雖然 Reviva Pharmaceuticals 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得投資。</p>
<p>在這裏查看這五隻股票</p>

RVPH

<p>Reviva Pharmaceuticals（納斯達克代碼：RVPH）的看漲期權交易量增加了 295%，共購入 25,745 份期權，而平均交易量為 6,521 份。分析師的評級意見不一，普遍共識為 “適度買入”，目標價為 3.86 美元。該股票開盤價為 0.32 美元，下跌 45.5%，市值為 3697 萬美元。機構投資者持有 63.18% 的股份</p>

<p>Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) saw unusually large options trading on Wednesday. Stock investors acquired 25,745 call options on the company. This is an increase of 295% compared to the average volume of 6,521 call options.</p>
<div class="lb-trans"><p>Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - 獲取免費報告) 週三的期權交易異常活躍。股票投資者購買了 25,745 份該公司的看漲期權。這比平均交易量 6,521 份看漲期權增加了 295%。</p>
</div><p>Get <strong>Reviva Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Reviva Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師升級和降級</h2>
</div><p>RVPH has been the topic of a number of research reports. D. Boral Capital reissued a &#34;buy&#34; rating and issued a $2.00 price objective on shares of Reviva Pharmaceuticals in a report on Tuesday. Benchmark dropped their price target on shares of Reviva Pharmaceuticals from $14.00 to $7.00 and set a &#34;speculative buy&#34; rating on the stock in a research note on Monday, September 15th. HC Wainwright lowered their target price on shares of Reviva Pharmaceuticals from $11.00 to $4.00 and set a &#34;buy&#34; rating on the stock in a report on Monday, October 27th. Weiss Ratings restated a &#34;sell (e+)&#34; rating on shares of Reviva Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Wall Street Zen upgraded Reviva Pharmaceuticals to a &#34;sell&#34; rating in a research note on Saturday, October 4th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $3.86.</p>
<div class="lb-trans"><p>RVPH 已成為多份研究報告的主題。D. Boral Capital 在週二的報告中重申了對 Reviva Pharmaceuticals 的 &#34;買入&#34; 評級，並設定了 2.00 美元的目標價。Benchmark 在 9 月 15 日的研究報告中將 Reviva Pharmaceuticals 的目標價從 14.00 美元下調至 7.00 美元，並對該股票設定了 &#34;投機性買入&#34; 評級。HC Wainwright 在 10 月 27 日的報告中將 Reviva Pharmaceuticals 的目標價從 11.00 美元下調至 4.00 美元，並對該股票設定了 &#34;買入&#34; 評級。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Reviva Pharmaceuticals 的 &#34;賣出 (e+)&#34; 評級。最後，Wall Street Zen 在 10 月 4 日的研究報告中將 Reviva Pharmaceuticals 的評級上調至 &#34;賣出&#34;。一位投資分析師對該股票給予了強烈買入評級，七位分析師給予了買入評級，一位分析師對該公司的股票給予了賣出評級。根據 MarketBeat 的數據，該股票的共識評級為 &#34;適度買入&#34;，共識目標價為 3.86 美元。</p>
</div><p><strong>Get Our Latest Analysis on RVPH</strong></p>
<div class="lb-trans"><p><strong>獲取我們對 RVPH 的最新分析</strong></p>
</div><h2>Reviva Pharmaceuticals Trading Down 45.5%</h2>
<div class="lb-trans"><h2>Reviva Pharmaceuticals 股價下跌 45.5%</h2>
</div><p>NASDAQ RVPH opened at $0.32 on Wednesday. The stock has a 50-day moving average of $0.57 and a 200-day moving average of $0.52. The firm has a market cap of $36.97 million, a PE ratio of -0.70 and a beta of -0.02. Reviva Pharmaceuticals has a 1-year low of $0.25 and a 1-year high of $2.17.</p>
<div class="lb-trans"><p>NASDAQ RVPH 週三開盤價為 0.32 美元。該股票的 50 日移動平均線為 0.57 美元，200 日移動平均線為 0.52 美元。該公司的市值為 3697 萬美元，市盈率為 -0.70，貝塔值為 -0.02。Reviva Pharmaceuticals 的一年低點為 0.25 美元，一年高點為 2.17 美元。</p>
</div><p>Reviva Pharmaceuticals (NASDAQ:RVPH - Get Free Report) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.05. As a group, equities research analysts forecast that Reviva Pharmaceuticals will post -0.97 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Reviva Pharmaceuticals (NASDAQ:RVPH - 獲取免費報告) 最近於 11 月 13 日發佈了季度財報。該公司報告每股收益為（0.06）美元，超出市場共識預期的（0.11）美元 0.05 美元。作為一個整體，股票研究分析師預測 Reviva Pharmaceuticals 本財年的每股收益將為 -0.97 美元。</p>
</div><h2>Institutional Trading of Reviva Pharmaceuticals</h2>
<div class="lb-trans"><h2>Reviva Pharmaceuticals 的機構交易</h2>
</div><p>Several hedge funds and other institutional investors have recently made changes to their positions in RVPH. Armistice Capital LLC bought a new position in Reviva Pharmaceuticals during the second quarter valued at approximately $1,026,000. 683 Capital Management LLC purchased a new stake in shares of Reviva Pharmaceuticals in the 2nd quarter worth $381,000. Persistent Asset Partners Ltd increased its position in Reviva Pharmaceuticals by 300.0% in the second quarter. Persistent Asset Partners Ltd now owns 641,174 shares of the company's stock worth $244,000 after buying an additional 480,864 shares in the last quarter. Millennium Management LLC raised its stake in Reviva Pharmaceuticals by 15.0% during the 3rd quarter. Millennium Management LLC now owns 1,711,221 shares of the company's stock worth $631,000 after acquiring an additional 223,178 shares during the period. Finally, Lido Advisors LLC bought a new stake in shares of Reviva Pharmaceuticals during the 3rd quarter valued at $37,000. Hedge funds and other institutional investors own 63.18% of the company's stock.</p>
<div class="lb-trans"><p>幾家對沖基金和其他機構投資者最近對 RVPH 的持倉進行了調整。Armistice Capital LLC 在第二季度購買了價值約 1,026,000 美元的 Reviva Pharmaceuticals 新頭寸。683 Capital Management LLC 在第二季度購買了價值 381,000 美元的 Reviva Pharmaceuticals 新股份。Persistent Asset Partners Ltd 在第二季度將其在 Reviva Pharmaceuticals 的持倉增加了 300.0%。Persistent Asset Partners Ltd 現在擁有 641,174 股該公司的股票，價值 244,000 美元，此前在上個季度又購買了 480,864 股。Millennium Management LLC 在第三季度將其在 Reviva Pharmaceuticals 的持倉增加了 15.0%。Millennium Management LLC 現在擁有 1,711,221 股該公司的股票，價值 631,000 美元，此前在此期間又收購了 223,178 股。最後，Lido Advisors LLC 在第三季度購買了價值 37,000 美元的 Reviva Pharmaceuticals 新股份。對沖基金和其他機構投資者持有該公司 63.18% 的股份。</p>
</div><h2>Reviva Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Reviva Pharmaceuticals 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Reviva Pharmaceuticals, Inc NASDAQ: RVPH is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.</p>
<div class="lb-trans"><p>Reviva Pharmaceuticals, Inc NASDAQ: RVPH 是一家專注於在美國和部分國際市場收購、開發和商業化處方藥產品的專業製藥公司。公司成立於 2002 年，總部位於佛羅里達州科勒爾蓋布爾斯，Reviva 主要針對那些未被充分推廣的、已過專利期的藥物，這些藥物的新劑型可以提高患者的依從性和治療效果。</p>
</div><p>The company's core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.</p>
<div class="lb-trans"><p>公司的核心活動包括識別 FDA 批准的藥物候選者，開發配方以滿足特定或服務不足的患者羣體——例如兒科和孤兒適應症——並支持監管申請。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Reviva Pharmaceuticals</li>
<li>The boring AI play that could pay up to $4,290 monthly</li>
<li>ALERT: Drop these 5 stocks before January 2026!</li>
<li>Trump’s “real estate deal for America” explained</li>
<li>A month before the crash</li>
<li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Reviva Pharmaceuticals</li>
<li>可能每月帶來高達 4,290 美元的無聊 AI 投資</li>
<li>警報：在 2026 年 1 月之前拋售這 5 只股票！</li>
<li>特朗普的 “美國房地產交易” 解釋</li>
<li>崩盤前一個月</li>
<li>在 1 月 1 日之前投資 1,000 美元於這隻股票 [不是 NVDA]</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Reviva Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元於 Reviva Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Reviva Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Reviva Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Reviva Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Reviva Pharmaceuticals 並不在名單上。</p>
</div><p>While Reviva Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Reviva Pharmaceuticals 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得投資。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

投資者大量購買 Reviva Pharmaceuticals（NASDAQ:RVPH）的看漲期權